|
Results relating to clinical change and study attrition. |
||||||
| Months |
Number of trials |
Chlorpromazine |
Placebo |
RR (95% CI) |
Test for heterogeneity |
|
|
|
||||||
| events/total participants |
||||||
|
|
||||||
| Relapse |
6–24 |
3 |
108/202 |
159/192 |
0.65 (0.5–9.0) |
Chi2 7.83, df 2, p = 0.02 I2 = 74.5%* |
| No global improvement |
2–6 |
13 |
470/654 |
406/467 |
0.76 (0.7–0.9) |
Chi2 25.4, df 12, p = 0.01 I2 = 52.8% |
| Leaving the study early |
6–24 |
2 |
38/254 |
33/238 |
1.09 (0.7–1.6) |
Chi2 0.47, df 1, p = 0.49 I2 = 0% |
|
* no clear cause of heterogeneity found on close re-inspection of trials | ||||||
Adams et al. BMC Medicine 2005 3:15 doi:10.1186/1741-7015-3-15 |
||||||